The complex relation between bisphosphonate adherence and fracture reduction.
BACKGROUND
Real-world adherence to bisphosphonate therapy is poor. Consistent data support a relation between medication adherence and fracture reduction, but relatively little attention has been paid to the effect of the method used to measure adherence on this relation or on the relation between adherence and specific fracture types.


OBJECTIVE
Our objective was to assess the relation between bisphosphonate adherence and the risk of hip, vertebral, distal forearm, and any fracture using different measures of adherence.


METHODS
We conducted a cohort study using administrative claims data. Adherence was assessed in sequential 60-d periods. In models incorporating time-varying measures of adherence, the adjusted relation between adherence and fracture was examined using several methods for calculating the proportion of days covered (PDC).


METHODS
Patients included community-dwelling elderly enrolled in a Pennsylvania pharmaceutical assistance program and Medicare initiating an oral bisphosphonate for osteoporosis.


METHODS
Risk of hip, vertebral, distal forearm, and any osteoporotic fracture was assessed.


RESULTS
Fractures occurred at a rate of 43 per 1000 person-years among the 19,987 patients meeting study eligibility criteria. There was an inverse relation between adherence and fracture rate for all adherence measures and fracture types, excluding distal forearm fractures. High (80-100%) cumulative PDC was associated with a 22% reduction in overall fracture rate, a 23% reduction in hip fracture rate, and 26% reduction in vertebral fracture rate.


CONCLUSIONS
We found a consistent relation between adherence with osteoporosis treatment and fracture reduction, regardless of method for measuring PDC. The similarity in results across adherence measures is likely due to the high correlation between them.
Patrick
Amanda R
AR
Divisions of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine, Brigham and Women's Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA. arpatrick@partners.org
Brookhart
M Alan
MA
Losina
Elena
E
Schousboe
John T
JT
Cadarette
Suzanne M
SM
Mogun
Helen
H
Solomon
Daniel H
DH
D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D015331:Cohort Studies; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology* / Q000517:prevention & control; D006306:Health Surveys; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D010414:Pennsylvania; D015995:Prevalence; D012044:Regression Analysis; D012306:Risk; D012307:Risk Factors; D016903:Drug Monitoring
D050071:Bone Density Conservation Agents; D004164:Diphosphonates
J Bone Miner Res. 2008 Sep;23(9):1435-41
18442318
Mayo Clin Proc. 2007 Dec;82(12):1493-501
18053457
Osteoporos Int. 2009 Nov;20(11):1969-72
19184268
Health Serv Res. 2003 Aug;38(4):1103-20
12968819
Mayo Clin Proc. 2006 Aug;81(8):1013-22
16901023
BMC Musculoskelet Disord. 2007 Sep 26;8:97
17897451
Osteoporos Int. 2007 Mar;18(3):271-7
17021945
Endocr Rev. 2002 Aug;23(4):570-8
12202472
Epidemiology. 1994 Sep;5(5):541-4
7986870
J Clin Epidemiol. 1992 Jul;45(7):703-14
1619449
JAMA. 1998 Dec 23-30;280(24):2077-82
9875874
Bone. 2007 Nov;41(5):882-7
17707710
Am J Epidemiol. 2007 Aug 1;166(3):348-54
17504779
J Clin Epidemiol. 1992 Jun;45(6):613-9
1607900
Br J Clin Pharmacol. 2008 Jul;66(1):117-27
18460036
Osteoporos Int. 2011 Mar;22(3):943-54
20532481
Osteoporos Int. 2008 Apr;19(4):511-7
17874028
Med Care. 2009 Jan;47(1):69-72
19106733
Bone. 2006 Jun;38(6):922-8
16330270
Health Econ. 2001 Oct;10(7):601-15
11747044
Value Health. 2008 Jan-Feb;11(1):44-7
18237359
J Bone Miner Res. 2007 Mar;22(3):465-75
17144789
Osteoporos Int. 2009 Jan;20(1):23-34
18521650